Other clinical data did not show significant antitumor activity of CSF1R inhibitors against relapsed or refractory classical Hodgkin lymphoma (116), implying limited clinical efficacy of targeting CSF-1 or CSF-1R and leading some companies to discontinue their myeloid targeting programs. This evidence concerns the gene CSF1R and Hodgkins lymphoma.